These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 19450080

  • 1. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

  • 2. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 4. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 5. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 6. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
    Borget I, Chouaid C, Demarteau N, Annemans L, Pujol JL.
    Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 8. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X, Long SR, Marder WD, Sullivan SD, Kallich J.
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [Abstract] [Full Text] [Related]

  • 9. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 10. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 11. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G, Hurley D, Whyte JL, Willey V, Wilson M, Kallich J.
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [Abstract] [Full Text] [Related]

  • 12. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 13. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct 20; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Oct 20; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 15. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD, Cooper B.
    Nephrology (Carlton); 2004 Aug 20; 9(4):223-8. PubMed ID: 15363054
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 20; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 17. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov 20; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 18. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT.
    Am J Ther; 2007 Nov 20; 14(4):322-7. PubMed ID: 17667204
    [Abstract] [Full Text] [Related]

  • 19. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
    Noxon V, Knopf KB, Norris LB, Chen B, Yang YT, Qureshi ZP, Hrushesky W, Lebby AA, Schooley B, Hikmet N, Dickson M, Thamer M, Cotter D, Yarnold PR, Bennett CL.
    J Oncol Pract; 2017 Jun 20; 13(6):e562-e573. PubMed ID: 28504901
    [Abstract] [Full Text] [Related]

  • 20. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.